astrazeneca imfinzi - Search News

China, AstraZeneca

Investor's Business Daily on MSN · 1h

AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Pharmaceutical Technology · 1h

AstraZeneca’s shares rise as it addresses China investigation

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).

Seeking Alpha on MSN · 8h

AstraZeneca gains as Q4 results clear China overhang

AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation. Read more here.

AstraZeneca faces potential fines in China

Hosted on MSN · 12h

Drugmaker AstraZeneca flags possible $4.5 million Chinese tax fine

AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its cancer drugs, the pharmaceuticals giant said on Thursday as it continues to gauge the impact of ongoing investigations in the key growth market.

FiercePharma · 7h

AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. | As AstraZeneca faces an ongoing investigation into alleged illegal importation of drugs in China,

The Mirror · 9h

Pharmaceutical giant AstraZeneca faces potential fines in China over import taxes

AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with other staff members by Chinese authorities

8h

AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China

AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...

AstraZeneca’s Imfinzi recommended by CHMP to treat small cell lung cancer

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

3d

AstraZeneca’s Imfinzi recommended for approval in EU by CHMP

Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...

8h

AstraZeneca boss denies falling out with Labour despite scrapping £450m factory

The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool ...

7h

AstraZeneca reports better than expected profit on higher cancer drug sales

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

9hon MSN

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site - Pascal Soriot, chief executive of AstraZeneca, ...

10h

AstraZeneca continues to ‘fully cooperate’ with Chinese authorities

The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results